Nifty
:
23622.90
Sensex
:
75527.95
461.30 (1.99%)
1695.40 (2.30%)
Nifty
Sensex
:
:
23622.90
75527.95
461.30 (1.99%)
1695.40 (2.30%)

Alkem Laboratories Ltd.

Pharmaceuticals & Drugs - Domestic

Rating :
73/99

BSE: 539523 | NSE: ALKEM

NSE BSE
5298.00
12-Jun-2026
  • Open
  • High
  • Low
  • Previous Close
  •  5340
  •  5358.5
  •  5283
  •  5301.50
  • Volume
  • Traded Value (lacs)
  • 52 Week High
  • 52 Week Low
  •  67310
  •  357891618.5
  •  5933.5
  •  4716.2

Stock Summary

  • Market Cap(Crs)
  • Stock P:E
  • Face Value
  • 63,322.22
  • 27.51
  • 2
  • Enterprise Value(Crs)
  • Dividend Yield
  • Price:Book Value
  • 63,212.82
  • 1.00%
  • 4.58

Shareholding Pattern

  • Promoter
  • Corporate
  • Public
  • 51.20%
  • 0.08%
  • 17.06%
  • FII
  • DII
  • Others
  • 10.15%
  • 19.75%
  • 1.76%

Chart

Price | P:E | P:BV | EV:EBITDA | MCap:Sales | EPS

Revenue CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 10.16
  • 7.90
  • 3.78

EBITDA CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 11.40
  • 5.28
  • 9.31

PAT CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 11.31
  • 6.45
  • 30.08

P:E (Median)

  • 8 Years
  • 5 Years
  • 3 Years
  • 28.58
  • 29.07
  • 30.97

P:BV (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • 4.87
  • 5.06
  • 5.35

EV:EBITDA (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • 20.19
  • 20.97
  • 21.78

Quarterly Results

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 26
Mar 25
Var%
Dec 25
Dec 24
Var%
Sep 25
Sep 24
Var%
Jun 25
Jun 24
Var%
Net Sales
3,603.32
3,143.75
14.62%
3,736.82
3,374.28
10.74%
4,000.99
3,414.67
17.17%
3,371.14
3,031.82
11.19%
Expenses
3,085.93
2,752.46
12.12%
2,908.82
2,614.89
11.24%
3,080.22
2,661.84
15.72%
2,632.09
2,423.18
8.62%
EBITDA
517.39
391.29
32.23%
828.00
759.39
9.03%
920.77
752.83
22.31%
739.05
608.64
21.43%
EBIDTM
14.36%
12.45%
22.16%
22.51%
23.01%
22.05%
21.92%
20.08%
Other Income
200.07
145.96
37.07%
143.10
92.99
53.89%
103.69
134.48
-22.90%
136.49
120.31
13.45%
Interest
53.88
28.42
89.58%
42.10
36.03
16.85%
35.02
28.14
24.45%
29.78
29.11
2.30%
Depreciation
105.76
112.49
-5.98%
95.01
85.28
11.41%
93.61
78.91
18.63%
87.68
80.48
8.95%
PBT
422.85
396.34
6.69%
781.20
731.07
6.86%
895.83
780.26
14.81%
771.01
619.36
24.48%
Tax
171.17
73.33
133.42%
127.67
90.28
41.42%
116.23
78.30
48.44%
102.69
69.12
48.57%
PAT
251.68
323.01
-22.08%
653.53
640.79
1.99%
779.60
701.96
11.06%
668.32
550.24
21.46%
PATM
6.98%
10.27%
17.49%
18.99%
19.49%
20.56%
19.82%
18.15%
EPS
19.78
25.58
-22.67%
53.20
52.35
1.62%
63.99
57.60
11.09%
55.56
45.60
21.84%

Annual Results

Consolidated Figures in Rs. Crores /

Standalone
Description
TTM
Mar 25
Mar 24
Mar 23
Mar 22
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Net Sales
14,712.27
12,964.52
12,667.58
11,599.26
10,634.19
8,865.01
8,344.36
7,357.19
6,391.84
5,687.53
4,924.84
Net Sales Growth
13.48%
2.34%
9.21%
9.08%
19.96%
6.24%
13.42%
15.10%
12.38%
15.49%
 
Cost Of Goods Sold
5,092.77
4,121.25
4,327.06
4,381.43
3,565.78
3,124.81
2,959.14
2,586.30
1,986.45
1,807.71
1,630.87
Gross Profit
9,619.50
8,843.27
8,340.52
7,217.83
7,068.41
5,740.20
5,385.22
4,770.89
4,405.39
3,879.82
3,293.97
GP Margin
65.38%
68.21%
65.84%
62.23%
66.47%
64.75%
64.54%
64.85%
68.92%
68.22%
66.88%
Total Expenditure
11,707.06
10,452.37
10,422.09
9,989.81
8,581.27
6,922.62
6,870.97
6,242.42
5,382.92
4,688.58
4,071.59
Power & Fuel Cost
-
168.99
162.58
163.94
162.96
129.95
130.14
121.48
112.64
86.34
66.33
% Of Sales
-
1.30%
1.28%
1.41%
1.53%
1.47%
1.56%
1.65%
1.76%
1.52%
1.35%
Employee Cost
-
2,453.92
2,201.01
2,131.35
1,962.71
1,621.03
1,505.49
1,362.46
1,191.64
1,003.85
861.08
% Of Sales
-
18.93%
17.38%
18.37%
18.46%
18.29%
18.04%
18.52%
18.64%
17.65%
17.48%
Manufacturing Exp.
-
1,282.95
1,183.76
972.37
1,092.63
748.03
765.43
806.17
838.87
692.26
550.16
% Of Sales
-
9.90%
9.34%
8.38%
10.27%
8.44%
9.17%
10.96%
13.12%
12.17%
11.17%
General & Admin Exp.
-
850.62
833.21
819.84
641.25
506.77
525.62
512.52
469.90
379.78
334.28
% Of Sales
-
6.56%
6.58%
7.07%
6.03%
5.72%
6.30%
6.97%
7.35%
6.68%
6.79%
Selling & Distn. Exp.
-
1,319.76
1,307.60
1,339.88
1,070.10
700.98
854.48
726.21
675.43
596.44
503.69
% Of Sales
-
10.18%
10.32%
11.55%
10.06%
7.91%
10.24%
9.87%
10.57%
10.49%
10.23%
Miscellaneous Exp.
-
254.88
406.87
181.00
85.84
91.05
130.67
127.28
107.99
122.20
503.69
% Of Sales
-
1.97%
3.21%
1.56%
0.81%
1.03%
1.57%
1.73%
1.69%
2.15%
2.54%
EBITDA
3,005.21
2,512.15
2,245.49
1,609.45
2,052.92
1,942.39
1,473.39
1,114.77
1,008.92
998.95
853.25
EBITDA Margin
20.43%
19.38%
17.73%
13.88%
19.30%
21.91%
17.66%
15.15%
15.78%
17.56%
17.33%
Other Income
583.35
493.74
310.84
216.08
162.65
233.21
104.22
87.70
115.42
112.01
239.71
Interest
160.78
121.70
112.41
107.36
52.37
58.92
65.06
54.63
55.33
45.16
71.24
Depreciation
382.06
357.16
299.30
310.42
303.96
274.58
252.76
193.18
143.03
101.17
93.31
PBT
2,870.89
2,527.03
2,144.62
1,407.75
1,859.24
1,842.10
1,259.79
954.66
925.98
964.63
928.41
Tax
517.76
311.03
211.67
297.96
163.96
224.33
110.48
181.02
287.56
59.96
176.18
Tax Rate
18.03%
12.31%
10.46%
22.84%
8.89%
12.18%
8.77%
18.96%
31.05%
6.22%
18.98%
PAT
2,353.13
2,166.10
1,795.77
984.17
1,645.62
1,585.02
1,127.07
760.51
630.94
892.03
741.59
PAT before Minority Interest
2,303.77
2,216.00
1,811.46
1,006.81
1,680.32
1,617.77
1,149.31
773.64
638.42
904.67
752.23
Minority Interest
-49.36
-49.90
-15.69
-22.64
-34.70
-32.75
-22.24
-13.13
-7.48
-12.64
-10.64
PAT Margin
15.99%
16.71%
14.18%
8.48%
15.47%
17.88%
13.51%
10.34%
9.87%
15.68%
15.06%
PAT Growth
6.19%
20.62%
82.47%
-40.19%
3.82%
40.63%
48.20%
20.54%
-29.27%
20.29%
 
EPS
196.75
181.11
150.15
82.29
137.59
132.53
94.24
63.59
52.75
74.58
62.01

Results Balance Sheet

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 25
Mar 24
Mar 23
Mar 22
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Shareholder's Funds
11,984.87
10,312.06
9,045.29
8,637.90
7,376.73
6,160.67
5,439.34
4,863.77
4,467.64
3,691.96
Share Capital
23.91
23.91
23.91
23.91
23.91
23.91
23.91
23.91
23.91
23.91
Total Reserves
11,924.81
10,268.61
9,020.78
8,613.39
7,351.70
6,135.40
5,413.93
4,838.87
4,443.34
3,668.03
Non-Current Liabilities
-445.76
-648.88
-688.00
-892.74
-750.71
-540.58
-288.92
-358.61
-400.78
-306.15
Secured Loans
62.42
40.00
0.00
0.03
18.47
63.60
219.80
122.12
175.01
112.49
Unsecured Loans
248.49
0.00
0.00
9.35
9.46
10.31
11.50
8.61
6.55
10.97
Long Term Provisions
338.22
299.86
369.36
332.75
250.73
222.98
173.72
150.27
102.17
82.96
Current Liabilities
3,958.69
3,994.55
3,707.15
4,805.34
3,604.05
3,244.58
2,217.53
2,383.31
1,689.69
1,537.60
Trade Payables
1,839.35
1,748.12
1,165.03
1,173.38
1,069.41
954.05
962.25
960.71
741.37
580.48
Other Current Liabilities
1,164.24
891.94
838.81
771.42
643.11
555.47
428.08
520.04
339.25
366.01
Short Term Borrowings
734.89
1,172.63
1,307.12
2,570.62
1,635.96
1,503.51
671.27
761.27
472.37
464.17
Short Term Provisions
220.21
181.86
396.19
289.92
255.57
231.55
155.93
141.29
136.70
126.94
Total Liabilities
15,946.56
14,060.07
12,454.15
12,759.93
10,411.35
9,012.97
7,500.56
7,010.02
5,871.78
5,018.43
Net Block
2,852.31
2,872.78
2,682.85
2,901.73
2,792.98
2,908.01
2,530.44
2,283.59
1,797.04
1,449.54
Gross Block
4,719.78
4,543.69
4,050.24
4,185.64
3,723.05
3,606.95
3,026.08
2,603.78
1,977.20
1,538.64
Accumulated Depreciation
1,867.47
1,670.91
1,367.39
1,283.91
930.07
698.94
495.64
320.19
180.16
89.10
Non Current Assets
5,007.03
3,648.49
3,724.47
4,324.50
3,482.53
3,507.32
3,284.43
2,996.80
2,954.64
2,249.73
Capital Work in Progress
548.07
158.57
323.24
339.48
393.28
362.97
492.96
380.97
299.26
172.42
Non Current Investment
943.24
334.80
304.61
231.67
153.95
91.50
95.74
98.45
259.44
234.39
Long Term Loans & Adv.
508.16
203.74
139.07
154.44
93.77
90.65
111.47
133.68
185.16
142.35
Other Non Current Assets
155.25
78.60
274.70
697.18
48.55
54.19
53.82
100.11
413.74
251.03
Current Assets
10,811.19
10,411.58
8,606.42
8,433.70
6,923.27
5,487.57
4,204.40
4,013.22
2,915.32
2,768.70
Current Investments
902.26
148.99
317.21
139.31
178.83
169.89
227.88
345.82
293.56
274.18
Inventories
2,922.41
2,661.18
2,607.53
3,005.53
2,312.44
1,818.82
1,499.87
1,442.19
1,206.00
909.37
Sundry Debtors
2,466.25
2,252.81
2,132.18
1,884.60
1,607.21
1,649.36
1,248.41
1,080.50
713.64
567.51
Cash & Bank
1,563.08
1,579.35
2,616.89
2,578.58
1,990.45
1,092.21
661.60
576.78
399.26
780.90
Other Current Assets
2,957.19
237.13
244.68
239.80
834.34
757.29
566.64
567.93
302.86
236.74
Short Term Loans & Adv.
2,800.91
3,532.12
687.93
585.88
504.70
482.24
405.00
390.63
171.35
141.30
Net Current Assets
6,852.50
6,417.03
4,899.27
3,628.36
3,319.22
2,242.99
1,986.87
1,629.91
1,225.63
1,231.10
Total Assets
15,818.22
14,060.07
12,330.89
12,758.20
10,405.80
8,994.89
7,488.83
7,010.02
5,869.96
5,018.43

Cash Flow

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 25
Mar 24
Mar 23
Mar 22
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Cash From Operating Activity
1,912.84
1,948.07
1,682.50
1,111.02
1,264.90
585.08
779.65
266.04
471.14
725.83
PBT
2,527.03
2,023.13
1,304.77
1,844.28
1,842.10
1,259.79
954.66
925.98
964.63
928.41
Adjustment
103.80
383.57
324.35
208.60
164.64
255.87
216.37
116.47
33.02
-14.42
Changes in Working Capital
-213.97
-51.69
326.77
-544.96
-341.16
-647.20
-140.27
-573.24
-262.55
10.05
Cash after chg. in Working capital
2,416.86
2,355.01
1,955.89
1,507.92
1,665.58
868.46
1,030.76
469.21
735.10
924.04
Interest Paid
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Tax Paid
-504.02
-406.94
-273.39
-396.90
-400.68
-283.38
-251.11
-203.17
-263.96
-198.21
Other Direct Exp. Paid
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Extra & Other Items
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Cash From Investing Activity
-1,298.76
-1,008.50
112.84
-1,435.13
-998.54
-741.35
-316.39
-357.23
-285.93
202.27
Net Fixed Assets
75.19
-74.10
-101.58
-278.91
-115.11
-310.63
-342.15
-531.27
-390.07
160.79
Net Investments
-1,577.80
176.57
-476.94
-376.23
-196.34
-260.44
-151.10
-26.86
-359.97
-87.11
Others
203.85
-1,110.97
691.36
-779.99
-687.09
-170.28
176.86
200.90
464.11
128.59
Cash from Financing Activity
-810.99
-1,145.01
-1,760.82
379.57
-271.75
79.15
-378.94
84.56
-137.88
-927.27
Net Cash Inflow / Outflow
-196.91
-205.44
34.52
55.46
-5.39
-77.12
84.32
-6.63
47.33
0.83
Opening Cash & Equivalents
66.31
273.80
232.18
174.22
175.94
249.05
166.71
166.63
127.03
123.75
Closing Cash & Equivalent
-120.09
66.31
273.80
232.18
174.22
175.94
249.05
166.71
166.63
127.05

Financial Ratios

Consolidated /

Standalone
Description
Mar 25
Mar 24
Mar 23
Mar 22
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Book Value (Rs.)
999.47
860.94
756.56
722.48
616.95
515.21
454.86
406.76
373.67
308.82
ROA
14.77%
13.66%
7.99%
14.50%
16.66%
13.92%
10.66%
9.91%
16.61%
14.59%
ROE
19.93%
18.74%
11.39%
20.99%
23.91%
19.82%
15.02%
13.69%
22.18%
22.47%
ROCE
21.56%
19.52%
13.09%
18.69%
22.56%
18.71%
16.49%
17.86%
21.31%
23.09%
Fixed Asset Turnover
4.17
4.51
4.36
3.84
3.56
3.74
3.80
3.75
3.33
3.07
Receivable days
44.62
41.28
40.86
41.72
45.33
42.66
39.69
38.15
39.95
39.57
Inventory Days
52.79
49.60
57.10
63.54
57.51
48.86
50.14
56.31
65.96
61.23
Payable days
158.86
122.87
97.40
114.79
118.18
52.05
60.17
61.04
52.36
49.96
Cash Conversion Cycle
-61.46
-31.98
0.57
-9.53
-15.34
39.47
29.66
33.42
53.55
50.84
Total Debt/Equity
0.09
0.12
0.14
0.30
0.23
0.26
0.17
0.21
0.15
0.18
Interest Cover
21.76
19.00
13.15
36.22
32.26
20.36
18.48
17.74
22.36
14.03

Annual Reports:

FY 2025
FY 2024
FY 2023
FY 2022
FY 2021
FY 2020
FY 2019
FY 2018
FY 2017
FY 2016

News Update:


  • Alkem Laboratories launches semaglutide in single-shot pre-filled syringes
    3rd Jun 2026, 09:50 AM

    The company is the first company in India to introduce semaglutide in single-shot pre-filled syringe format

    Read More
  • Alkem Laboratories - Quarterly Results
    29th May 2026, 00:00 AM

    Read More
  • Alkem Laboratories reports 23% fall in Q4 consolidated net profit
    28th May 2026, 18:06 PM

    Consolidated total income of the company increased by 15.61% at Rs 3,803.39 crore for Q4FY26

    Read More
  • USFDA completes inspection at Alkem Laboratories’ CRO facility in Taloja
    9th May 2026, 12:18 PM

    At the end of the inspection, no form 483 was issued

    Read More
  • Alkem Laboratories incorporates wholly owned subsidiary in UAE
    13th Apr 2026, 16:42 PM

    The new entity has been incorporated with a view to export the company’s products to African, South East Asian and non-UAE markets

    Read More
  • Alkem Laboratories launches everyday multivitamin supplement ‘A to Z Daily’
    7th Apr 2026, 16:00 PM

    The product is approved by the Food Safety Standards Authority of India

    Read More
  • Alkem Laboratories incorporates subsidiary in Dubai Healthcare City
    31st Mar 2026, 16:12 PM

    Alkem Pharmaceuticals has been incorporated to undertake the activities of manufacturing products and obtaining product registrations, except trading activities

    Read More
  • Alkem Laboratories launches semaglutide injection in India
    23rd Mar 2026, 10:30 AM

    The company has launched its semaglutide pre-filled disposable injection pen at a price starting Rs 1,800 for a month’s dosage, which translates into a weekly cost of Rs 450

    Read More
  • Alkem Laboratories gets certificate of GMP Compliance of Manufacturer for Baddi facility
    16th Mar 2026, 12:00 PM

    The said certificate is valid for a period of three years from the date of inspection

    Read More

Source: www.accordfintech.com | DISCLAIMER: Information is provided " as is" and solely for informational purposes, not for trading purposes or advice, and may be delayed.